SCHEMBL472760

SCHEMBL472760

CCCCCCCC1=Nc2ccccc2C(=O)C1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.42
NR1H2 P55055 1/20 0.40
NR1H3 Q13133 1/20 0.40
KCNH2 Q12809 2/20 0.37
GPR84 Q9NQS5 1/20 0.36
CES1 P23141 2/20 0.35
CDC25A P30304 1/20 0.35
GPR3 P46089 1/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 1/20 0.35
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
LIPG Q9Y5X9 1/20 0.34
ACHE P22303 1/20 0.34
BACE1 P56817 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
SOAT1 P35610 4/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21065455 1.00 PTPN1 (0.42) PTPN1NR1H2NR1H3KCNH2GPR84
SCHEMBL2821603 0.98 PTPN1 (0.40) PTPN1NR1H2NR1H3KCNH2GPR84
SCHEMBL8780480 0.94 PTPN1 (0.35) PTPN1NR1H2NR1H3CES1CDC25A
Phosphoric Acid SCHEMBL27784283 0.92 CETP (0.39) PTPN1NR1H2NR1H3
SCHEMBL9175519 0.88 SHMT2 (0.34) PTPN1CES1LMNATSHRL3MBTL1
SCHEMBL4764684 0.81 SHMT2 (0.39) CES1LMNATSHRTDP1L3MBTL1
SCHEMBL9361210 0.81 EPHX2 (0.37) LMNATDP1L3MBTL1
SCHEMBL28246116 0.78 KCNH2 (0.41) KCNH2TDP1L3MBTL1LIPGSIGMAR1
SCHEMBL3014252 0.78 ALDH1A1 (0.36) CES1LMNATSHRTDP1L3MBTL1
SCHEMBL7913644 0.77 TDP1 (0.39) PTPN1NR1H2NR1H3TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230184759-A1 IN VITRO METHOD FOR DETECTION OF INFECTIONS CAUSED BY PSEUDOMONAS AERUGINOSA CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2023-06-15 US claimed
EP-4126820-A1 IN VITRO METHOD FOR DETECTION OF INFECTIONS CAUSED BY PSEUDOMONAS AERUGINOSA Consejo Superior De Investigaciones Científicas (ES) 2023-02-08 EP claimed
WO-2021198064-A1 IN VITRO METHOD FOR DETECTION OF INFECTIONS CAUSED BY PSEUDOMONAS AERUGINOSA CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) 2021-10-07 WO claimed
US-20260138981-A1 DIHYDROFOLATE REDUCTASE INHIBITORS FOR ANTI-BIOTIC RESISTANT INFECTIONS THE TRUSTEES OF PRINCETON UNIV (US) 2026-05-21 US disclosed
EP-4702981-A1 TARGETED ANTIBACTERIAL TREATMENT Københavns Universitet (DK) 2026-03-04 EP disclosed
CN-120761536-A Detection and application for detecting pseudomonas aeruginosa metabolite based on HPLC-MS/MS 长沙市食品药品检验所 2025-10-10 CN disclosed
WO-2024077235-A9 DIHYDROFOLATE REDUCTASE INHIBITORS FOR ANTI-BIOTIC RESISTANT INFECTIONS THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2024-06-27 WO disclosed
WO-2024077235-A2 DIHYDROFOLATE REDUCTASE INHIBITORS FOR ANTI-BIOTIC RESISTANT INFECTIONS THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2024-04-11 WO disclosed
US-20230184759-A1 IN VITRO METHOD FOR DETECTION OF INFECTIONS CAUSED BY PSEUDOMONAS AERUGINOSA CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2023-06-15 US disclosed
US-11596626-B2 Compound for use against pathogenic Neisseria and Haemophilus species and Moraxella catarrhalis Universität Konstanz (DE) 2023-03-07 US disclosed
EP-4126820-A1 IN VITRO METHOD FOR DETECTION OF INFECTIONS CAUSED BY PSEUDOMONAS AERUGINOSA Consejo Superior De Investigaciones Científicas (ES) 2023-02-08 EP disclosed
EP-3475260-A1 COMPOUNDS FOR USE AS AN ANTI-BACTERIAL OR ANTI-FUNGAL AGENT AND AS A ZINC SENSOR Universität Konstanz (DE) 2019-05-01 EP disclosed
EP-2997382-B1 ALKYL QUINOLONES AS BIOMARKERS OF PSEUDOMONAS AERUGINOSA INFECTION AND USES THEREOF UNIV NOTTINGHAM (GB) 2018-07-11 EP disclosed
CN-107613967-A Host Defense Protein (HDP) mimetics for preventing and/or treating inflammatory diseases of the gastrointestinal tract 创新制药公司 2018-01-19 CN disclosed
WO-2017220205-A1 COMPOUNDS FOR USE AS AN ANTI-BACTERIAL OR ANTI-FUNGAL AGENT AND AS A ZINC SENSOR Universität Konstanz (DE) 2017-12-28 WO disclosed
EP-3260445-A1 COMPOUNDS FOR USE AS AN ANTI-BACTERIAL OR ANTI-FUNGAL AGENT AND AS A ZINC SENSOR Universität Konstanz (DE) 2017-12-27 EP disclosed
EP-2598651-A1 METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND ASSOCIATED WITH BACTERIAL INFECTION Sanofi-Aventis Deutschland GmbH (DE) 2013-06-05 EP disclosed
US-20130123360-A1 METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND ASSOCIATED WITH BACTERIAL INFECTION SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2013-05-16 US disclosed
WO-2012013621-A1 METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND ASSOCIATED WITH BACTERIAL INFECTION SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2012-02-02 WO disclosed
EP-2412819-A1 Methods and uses relating to the identification of compound associated with bacterial infection Sanofi-Aventis Deutschland GmbH (DE) 2012-02-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11596626-B2 Compound for use against pathogenic Neisseria and Haemophilus species and Moraxella catarrhalis MLEC, MPO, B3GNT2 PTPN1 3261/4885NR1H2 1226/4885NR1H3 1263/4885
US-20230184759-A1 IN VITRO METHOD FOR DETECTION OF INFECTIONS CAUSED BY PSEUDOMONAS AERUGINOSA QSOX1, QARS1, CD47 PTPN1 22/4885NR1H2 2554/4885NR1H3 2344/4885
US-20260138981-A1 DIHYDROFOLATE REDUCTASE INHIBITORS FOR ANTI-BIOTIC RESISTANT INFECTIONS DHFR, CBR1, DHRS9 PTPN1 2329/4885NR1H2 175/4885NR1H3 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.